A Study on How NNC0174-1213 Works in People With Overweight or Obesity
Phase 1
177
about 1.5 years
18–55
Male only
2 sites in TX, UT
What this study is about
Researchers are testing a new medicine called NNC0174-1213 to treat people with overweight or obesity. The aim of it is to see if the medicine is safe, how it works in human body, and what human body does to it medicine. Participants will either get the new medicine NNC0174-1213, a trial medicine called cagrilintide or a placebo (a dummy medicine similar to the new trial medicine and trial medicine but without active ingredients). Which treatment participants will get is decided by chance. The new trial medicine and it medicine are potential new medicines which cannot be prescribed by doctors. It will last for about a year in total.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cagrilintide B
- 2.Take NNC0174-1213 A
- 3.Take Placebo A (NNC0174 1213 A)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213, Part B: Number of treatment emergent adverse events (TEAE)
Secondary: Part A: AUC; area under the NNC0174 1213 plasma concentration-time curve, Part A: Cmax; maximum observed NNC0174 1213 plasma concentration, Part B: AUC; area under the NNC0174 1213 plasma concentration-time curve, Part B: Cmax; maximum observed NNC0174 1213 plasma concentration
Endocrinology